Key facts
| Price (PPV) | 35,486 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | agalsidase bêta |
| Class | Other alimentary tract and metabolism products |
| ATC code | A16AB04 |
| Manufacturer | SANOFI AVENTIS MAROC |
| Presentation | Boite de 1 flacon de 20 ml |
| Hospital price | 34,798 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement enzymatique substitutif chez les patients atteints de la maladie de Fabry (déficit en α-galactosidase A). Les données concernant l’efficacité et la sécurité ont été évaluées pour une durée de traitement allant jusqu’à 18 mois.
Find an open pharmacy
On-call pharmacies near you
About Fabrazyme 35 mg
Fabrazyme 35 mg belongs to the other alimentary tract and metabolism products therapeutic class. In Morocco, this drug is marketed by SANOFI AVENTIS MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Fabrazyme 35 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Fabrazyme 35 mg
Answers to common questions from Moroccan patients about this drug.